Giambattista Siepe1, Milly Buwenge2, Nam P Nguyen3, Gabriella Macchia4, Francesco Deodato4, Savino Cilla5, Gian C Mattiucci6, Ilaria Capocaccia2, Silvia Cammelli2, Alessandra Guido2, Alessandra Arcelli2, Maria Ntreta2, Sara Guerri7, Alessio G Morganti2. 1. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy giambattista.siepe@gmail.com. 2. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. 3. Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, U.S.A. 4. Radiotherapy Unit, Fondazione "Giovanni Paolo II", Catholic University of Sacred Heart, Campobasso, Italy. 5. Medical Physic Unit, Fondazione "Giovanni Paolo II", Catholic University of Sacred Heart, Campobasso, Italy. 6. Radiation Oncology Department, Università Cattolica del Sacro Cuore, Rome, Italy. 7. Department of Experimental and Specialty Medicine (DIMES), Division of Radiology S. Orsola - Malpighi Hospital, University of Bologna, Bologna, Italy.
Abstract
BACKGROUND/AIM: A systematic review on toxicity, local control (LC), overall survival (OS), and biochemical relapse-free survival (bRFS) after postoperative hypofractionated radiotherapy (HFRT) on prostate cancer (PCa) was performed. MATERIALS AND METHODS: Based on the PRISMA methodology, studies reporting clinical results after adjuvant or salvage HFRT were included. RESULTS: A total of 1,208 patients from 17 eligible studies were included. Median follow-up was 30 months. No case of severe acute gastrointestinal (GI) toxicity was recorded. Grade ≥3 acute genitourinary (GU) toxicity ranged between 0% and 3%. Different rates of grade ≥2 late GI (range=0-8.7%) and GU (range=0-66%) toxicity were recorded. Encouraging results on LC, OS, and bRFS were reported. CONCLUSION: Acute toxicity does not seem to be increased in patients receiving postoperative HFRT, but the results of late-GU toxicity are conflicting. Further prospective studies are needed before including postoperative HFRT in clinical practice. Copyright
BACKGROUND/AIM: A systematic review on toxicity, local control (LC), overall survival (OS), and biochemical relapse-free survival (bRFS) after postoperative hypofractionated radiotherapy (HFRT) on prostate cancer (PCa) was performed. MATERIALS AND METHODS: Based on the PRISMA methodology, studies reporting clinical results after adjuvant or salvage HFRT were included. RESULTS: A total of 1,208 patients from 17 eligible studies were included. Median follow-up was 30 months. No case of severe acute gastrointestinal (GI) toxicity was recorded. Grade ≥3 acute genitourinary (GU) toxicity ranged between 0% and 3%. Different rates of grade ≥2 late GI (range=0-8.7%) and GU (range=0-66%) toxicity were recorded. Encouraging results on LC, OS, and bRFS were reported. CONCLUSION: Acute toxicity does not seem to be increased in patients receiving postoperative HFRT, but the results of late-GU toxicity are conflicting. Further prospective studies are needed before including postoperative HFRT in clinical practice. Copyright
Authors: F H E Staal; J Janssen; C L Brouwer; J A Langendijk; K Ng Wei Siang; E Schuit; I J de Jong; J F Verzijlbergen; R J Smeenk; S Aluwini Journal: BMC Cancer Date: 2022-04-15 Impact factor: 4.638
Authors: Francesco Cuccia; Gianluca Mortellaro; Vincenzo Serretta; Vito Valenti; Antonella Tripoli; Marina Gueci; Nicoletta Luca; Antonio Lo Casto; Giuseppe Ferrera Journal: Cancer Manag Res Date: 2018-10-29 Impact factor: 3.989